ICUCW
SeaStar Medical Holding Corporation
NASDAQ · Healthcare · Biotechnology · US
$0.02
+0.00%Year over year
Reported trailing growth
- Revenue
- +123.6%
- EBITDA
- +6.6%
- EBIT
- +5.5%
- EPS
- +84.7%
- Free cash flow
- +10.8%
- Operating cash flow
- +10.8%
Forward estimates
Based on analyst estimates
- Revenue
- -41.6%
- EBITDA
- —
- EPS
- +52.9%
Three-year CAGR
- Revenue
- +814.1%
- EBITDA
- +50.5%
- EBIT
- +31.8%
- Net income
- +51.1%
- EPS
- +91.2%
- Free cash flow
- +15.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026